You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Primary Central Nervous System Lymphoma

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Primary CNS Lymphoma and Primary Vitreoretinal Lymphoma Trial (intensity-modulated radiotherapy (IMRT))

Not yet recruiting
  • Primary Central Nervous System Lymphoma and Primary Vitreoretinal Lymphoma
  • intensity-modulated radiotherapy (IMRT)
  • (no location specified)
Jun 4, 2023

Relapsed or Refractory (R/R) Primary CNS Lymphoma Trial in Nanjing (thiotepa combined with pomalidomide)

Recruiting
  • Relapsed or Refractory (R/R) Primary Central Nervous System Lymphoma
  • thiotepa combined with pomalidomide
  • Nanjing, Jiangsu, China
    Jiangsu Province People's Hospital.
Jun 27, 2023

Primary CNS Lymphoma Trial in Hangzhou (Rituximab, Lenalidomide, Methotrexate)

Completed
  • Primary Central Nervous System Lymphoma
  • Hangzhou, Zhejiang, China
    2nd Affiliated Hospital, School of Medicine, Zhejiang University
Nov 18, 2022

Primary CNS Lymphoma Trial in Hanzhou (Orelabrutinib, Rituximab, Methotrexate)

Recruiting
  • Primary Central Nervous System Lymphoma
  • Hanzhou, Zhejiang, China
    2nd Affiliated Hospital, School of Medicine, Zhejiang University
Nov 3, 2022

Refractory CNS Lymphoma, Relapsed Primary CNS Lymphoma, Primary CNS Lymphoma Trial in Hangzhou (Nivolumab)

Active, not recruiting
  • Refractory Central Nervous System Lymphoma
  • +2 more
  • Hangzhou, Zhejiang, China
    Jianmin Zhang
Jul 3, 2022

Primary CNS Lymphoma Trial in Paris (Glucarpidase, Methotrexate (MTX))

Recruiting
  • Primary Central Nervous System Lymphoma
  • Paris, France
    Hôpital Pitié-Salpêtrière
Oct 24, 2022

Non-hodgkin Lymphoma Trial (Methotrexate, Rituximab (where available), Ibrutinib)

Not yet recruiting
  • Non-hodgkin Lymphoma
  • (no location specified)
Aug 11, 2023

Newly-diagnosed PCNSL Treated WithMethotrexate and

Active, not recruiting
  • Primary Central Nervous System Lymphoma
  • Shanghai, China
    Department of Hematology, Huashan Hospital, Fudan University
Oct 30, 2023

Primary CNS Lymphoma Trial in Beijing (Orelabrutinib,Rituximab and Methotrexate)

Recruiting
  • Primary Central Nervous System Lymphoma
  • Orelabrutinib,Rituximab and Methotrexate
  • Beijing, Beijing, China
    Hospital 307
Sep 19, 2022

Primary CNS Lymphoma, Secondary CNS Lymphoma Trial in Beijing (GNC-038)

Recruiting
  • Primary Central Nervous System Lymphoma
  • Secondary Central Nervous System Lymphoma
  • Beijing, Beijing, China
    Beijing Tiantan Hospital, Capital Medical University
Jul 31, 2022

Primary CNS Lymphoma Trial in Shanghai (Orelabrutinib)

Recruiting
  • Primary Central Nervous System Lymphoma
  • Shanghai, Shanghai, China
    Ruijin Hospital
Apr 18, 2022

Primary CNS Lymphoma Trial in Paris (PET-MRI)

Not yet recruiting
  • Primary Central Nervous System Lymphoma
  • Paris, France
    Hôpital Pitié Salpêtrière
May 20, 2022

Primary CNS Lymphoma, Secondary CNS Lymphoma, Relapsed Cancer Trial in Miami (drug, procedure, radiation)

Not yet recruiting
  • Primary Central Nervous System Lymphoma
  • +3 more
  • Miami, Florida
    Miami Cancer Institute at Baptist Health, Inc.
Dec 23, 2022

Primary CNS Lymphoma Trial in Zhengzhou (the dose-escalation phase)

Recruiting
  • Primary Central Nervous System Lymphoma
  • the dose-escalation phase
  • Zhengzhou, Henan, China
    Oncology Department of The First Affiliated Hospital of Zhengzho
May 30, 2022

Primary CNS Lymphoma Trial in Beijing (Camrelizumab)

Recruiting
  • Primary Central Nervous System Lymphoma
  • Beijing, China
    Sanbo Brain Hospital Capital Medical University
Feb 10, 2022

Primary CNS Lymphoma Trial in Shanghai (Orelabrutinib, Rituximab, Methotrexate (MTX))

Recruiting
  • Primary Central Nervous System Lymphoma
  • Shanghai, Shanghai, China
    Department of Hematology, Huashan Hospital, Fudan University
Jul 26, 2022

Primary CNS Lymphoma Trial (Penpulimab)

Not yet recruiting
  • Primary Central Nervous System Lymphoma
  • (no location specified)
Apr 20, 2022

CNS Lymphoma Trial in Aarhus (Immunochemo)

Completed
  • Central Nervous System Lymphoma
  • Aarhus, Denmark
    Elisa Jacobsen Pulczynski
Aug 3, 2022

Immunohistochemical, Histological and Radiological Factors in

Not yet recruiting
  • Rare Disease With Poor Outcome
    • (no location specified)
    Apr 20, 2022

    CNS Lymphoma, Primary CNS Lymphoma, Secondary CNS Lymphoma Trial in San Francisco (Tafasitamab, Lenalidomide)

    Recruiting
    • CNS Lymphoma
    • +2 more
    • San Francisco, California
      University of California, San Francisco
    Aug 10, 2022

    Non-Hodgkin Lymphoma Trial in Cologne (Tafasitamab, Lenalidomide, Rituximab)

    Not yet recruiting
    • Non-Hodgkin Lymphoma
    • Cologne, Germany
      University of Cologne
    Oct 14, 2022

    CNS Lymphoma Trial in Seongnam-si (lenalidomide)

    Recruiting
    • Central Nervous System Lymphoma
    • Seongnam-si, Please Select, Korea, Republic of
      Seoul National University Bundang Hospital
    Feb 18, 2022

    Primary CNS Lymphoma, Secondary CNS Lymphoma Trial in Saint Louis (Durvalumab, Acalabrutinib)

    Recruiting
    • Primary Central Nervous System Lymphoma
    • Secondary Central Nervous System Lymphoma
    • Saint Louis, Missouri
      Washington University School of Medicine
    Mar 14, 2022

    Primary CNS Lymphoma Trial in Beijing (Orelabrutinib, Pomalidomide, Rituximab)

    Recruiting
    • Primary Central Nervous System Lymphoma
    • Beijing, Beijing, China
    • +2 more
    May 19, 2022

    Factors in Patients With Primary Central Nervous System Lymphoma

    Recruiting
    • PCNSL
    • Survival Analysis
    • prognostic marker
    • Zhengzhou, Henan, China
      Zhengzhou university
    Dec 12, 2021